Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 10/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | THRA | P10827 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL914446 | 0.84 | CRHR1 (0.41) | NOTUMALDH1A1TSHRHSD17B10CRHR1 | |
| SCHEMBL3931135 | 0.84 | GSK3B (0.48) | GSK3BPTPN1ALDH1A1TSHRHSD17B10 | |
| SCHEMBL12942492 | 0.72 | TACR1 (0.40) | ALDH1A1TSHRHPGD | |
| SCHEMBL9955538 | 0.71 | NOTUM (0.59) | GSK3BPTPN1NOTUM | |
| SCHEMBL3995406 | 0.69 | GSK3B (0.59) | GSK3BPTPN1 | |
| SCHEMBL7779146 | 0.69 | PTPN1 (0.58) | GSK3BPTPN1NOTUM | |
| SCHEMBL30580694 | 0.69 | PTPN1 (0.58) | GSK3BPTPN1NOTUM | |
| SCHEMBL29977001 | 0.69 | HPGD (0.57) | GSK3BPTPN1ALDH1A1TSHRHPGD | |
| SCHEMBL31149832 | 0.69 | PTPN1 (0.57) | GSK3BPTPN1 | |
| SCHEMBL1232165 | 0.69 | HPGD (0.57) | GSK3BPTPN1ALDH1A1TSHRHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2808020-A1 | Beta-Amyloid Pet Imaging Agents | The Government Of The United States, As Represented by The Secretary Of Health And Human Services (US) | 2014-12-03 | — | — | EP | disclosed |
| US-20140341812-A1 | BETA-AMYLOID PET IMAGING AGENTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2014-11-20 | — | — | US | disclosed |
| EP-2021340-B1 | BETA-AMYLOID PET IMAGING AGENTS | US GOVERNMENT (US) | 2014-07-23 | — | — | EP | disclosed |
| US-8703096-B2 | Beta-amyloid PET imaging agents | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2014-04-22 | — | — | US | disclosed |
| US-20110008255-A1 | BETA-AMYLOID PET IMAGING AGENTS | THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2011-01-13 | — | — | US | disclosed |
| EP-2021340-A2 | BETA-AMYLOID PET IMAGING AGENTS | The Government Of The United States, As Represented by The Secretary Of Health And Human Services (US) | 2009-02-11 | — | — | EP | disclosed |
| WO-2007124345-A2 | BETA-AMYLOID PET IMAGING AGENTS | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF HEALTH AND HUMAN SERVICES (US) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110008255-A1 | BETA-AMYLOID PET IMAGING AGENTS | APP, BACE1, PSEN1 | GSK3B 1265/4885PTPN1 4743/4885NOTUM 2180/4885 |
| US-20140341812-A1 | BETA-AMYLOID PET IMAGING AGENTS | APP, BACE1, PSEN1 | GSK3B 1265/4885PTPN1 4743/4885NOTUM 2180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.